FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

ペプチドライブラリー

Glutathione

GSH / L-Glutathione / Gamma-Glutamylcysteinylglycine

Beauty & Skincare

Glutathione is a tripeptide (gamma-glutamylcysteinylglycine) naturally synthesized in all human cells, serving as the body's primary endogenous antioxidant and detoxification molecule. It plays a central role in neutralizing reactive oxygen species, recycling other antioxidants like vitamins C and E, and supporting Phase II liver detoxification. Research applications span IV glutathione protocols in integrative medicine, skin depigmentation studies, and adjunctive therapy in neurodegenerative and hepatic conditions.

作用機序

Endogenous tripeptide (glutamate-cysteine-glycine) and the body's master antioxidant. Neutralizes reactive oxygen species, regenerates vitamins C and E, detoxifies xenobiotics via conjugation, and inhibits melanin synthesis by switching from eumelanin to pheomelanin production.

研究プロトコル

研究目的のみで使用。医療アドバイスではありません。

IV protocols use 600-1200mg once or twice weekly for skin brightening. Oral bioavailability is poor; liposomal glutathione at 500-1000mg daily studied. Nebulized glutathione at 300-600mg for respiratory applications.

研究ノート

Clinical Research Status

Glutathione has been studied extensively in clinical trials for conditions including Parkinson's disease, non-alcoholic fatty liver disease, cystic fibrosis, and HIV/AIDS-associated wasting. IV glutathione is widely administered in wellness and aesthetic clinics for skin brightening and systemic detoxification, though regulatory approval varies by jurisdiction. Oral bioavailability remains debated, driving interest in liposomal, sublingual, and IV delivery methods.

Key Published Findings

Studies have demonstrated that IV glutathione can reduce melanin index scores in human subjects, supporting its use in skin lightening protocols. Research in Parkinson's patients showed modest symptomatic improvement with IV administration in early open-label trials, though larger controlled trials have yielded mixed results. Depleted glutathione levels have been consistently associated with increased oxidative stress markers across multiple chronic disease states.

Safety Profile

Glutathione is generally considered safe with minimal adverse effects at standard supplemental and IV doses. Reported side effects are rare and typically mild, including bloating with oral forms or transient discomfort at IV infusion sites. Long-term high-dose safety data remains limited, and theoretical concerns exist about potential rebound oxidative stress upon abrupt discontinuation of IV protocols.

Drug Interactions & Contraindications

Glutathione may interact with chemotherapy agents by potentially reducing their efficacy through enhanced detoxification of cytotoxic drugs. Caution is advised in patients taking acetaminophen at high doses, as glutathione depletion is the mechanism of hepatotoxicity. Individuals with sulfite sensitivity should exercise caution, and concurrent use with nitroglycerin may potentiate hypotensive effects.

Comparison to Related Compounds

N-acetylcysteine (NAC) serves as a glutathione precursor with better-established oral bioavailability and is often preferred for raising intracellular glutathione levels. Alpha-lipoic acid works synergistically by recycling glutathione and is frequently co-administered in IV protocols. S-acetyl glutathione and liposomal glutathione represent newer oral formulations designed to overcome the bioavailability limitations of reduced glutathione.

Community Observations

Practitioners commonly report visible skin brightening effects after 6-10 IV sessions at doses of 1200-2000mg, though individual responses vary considerably. Users frequently combine glutathione with vitamin C IVs, reporting enhanced effects on skin clarity and energy levels. The peptide community generally regards glutathione as a foundational wellness molecule with an excellent safety record rather than a performance-enhancing compound.

半減期

~10-15 minutes (IV); ~2 hours (oral)

再構成

Sterile saline for IV push or drip

保存

乾燥粉末

Refrigerate 2-8C. Protect from light. Oxidizes rapidly.

再溶解

Use immediately after preparation. Extremely labile.

米国法的状況

Supplement (not FDA-regulated as drug)

また知られる名前

GSHL-GlutathioneGamma-Glutamylcysteinylglycine

よくある質問

Glutathioneとは何ですか?

Glutathione is a tripeptide (gamma-glutamylcysteinylglycine) naturally synthesized in all human cells, serving as the body's primary endogenous antioxidant and detoxification molecule. It plays a central role in neutralizing reactive oxygen species, recycling other antioxidants like vitamins C and E, and supporting Phase II liver detoxification. Research applications span IV glutathione protocols in integrative medicine, skin depigmentation studies, and adjunctive therapy in neurodegenerative and hepatic conditions.

Glutathioneはどのように作用しますか?

Endogenous tripeptide (glutamate-cysteine-glycine) and the body's master antioxidant. Neutralizes reactive oxygen species, regenerates vitamins C and E, detoxifies xenobiotics via conjugation, and inhibits melanin synthesis by switching from eumelanin to pheomelanin production.

Glutathioneの米国での規制状況は?

Supplement (not FDA-regulated as drug)

Glutathioneの半減期は?

~10-15 minutes (IV); ~2 hours (oral)

Glutathioneの別名は?

GSH, L-Glutathione, Gamma-Glutamylcysteinylglycine

ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。

完全な免責事項を読む